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Methods: Human umbilical endothelial cells were cultured to confluence and stimulated
with either thrombin or histamine with or without inhibitors of protein kinases possibly
involved in the regulation of eNOS activity. Phosphorylation of eNOS was analyzed with a
phosphospecific eNOS(Ser1179) antibody by Western blotting.
Results: Stimulation (using short term 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ment) or inhibition (by GF 109203X) of protein kinase C had no effect on eNOS phospho-
rylation and neither did the Rho-dependent kinase inhibitorY27632, the calmodulin
kinase inhibitor KN-62, the ERK-inhibitor PD98059 or the p38 inhibitor SB203580. Con-
versly, H89 which is an inhibitor of both protein kinase A (PKA) and the AMP-activated
kinase (AMPK) strongly inhibited eNOS phosphorylation. Neither thrombin nor histamine
caused a rise in endothelial cyclic-AMP and neither forskolin nor dibutyryl-cyclic-AMP
affected eNOS phosphorylation contradicting the possible role of PKA in the activation
pathway. On the other hand, thrombin and histamine caused phosphorylation of the
AMPK downstream substances acetyl-CoA carboxylase and elongation factor-2.
Conclusion: The G-protein activators thrombin and histamine stimulate eNOS phospho-
rylation on Ser1179 via an Akt-independent, AMPK-dependent pathway.
1122-175 Ox-Low-Density Lipoprotein Are Potent Antigens for 
Dendritic Cell in Plaque Instability: Role of 
Lipoxygenase-1
Fabrizio Clementi, Sandro Grelli, Ruggiero Mango, Massimo Federici, Luigi Franchi, 
Andrea Amato, Giovanni Battista Forleo, Gaetano Chiricolo, Massimo Marchei, Lucia De 
Luca, Mark Gallagher, Cartesio Favalli, Renato Lauro, Giuseppe Novelli, Francesco 
Romeo, University of Rome Tor Vergata, Rome, Italy
Experimental data identify ox-LDL has the most important antigens in atherosclerosis
and plaque rupture. Recently, we identified lectin-like oxidized low-density lipoprotein
receptor (LOX-1), as a susceptibility gene for myocardial infarction. Experimental data
had shown that ox-LDL are a potent stimulus for maturation of monocyte derived den-
dritic cells (MDDC). MDDC stimulated by ox-LDL are able to activate T-lymphocyte
toward a Th1 response similar to that observed during the acute phases of coronary
instability.
We hypothesized that LOX-1 could be involved in ox-LDL induced maturation of MDDC
and could drive the activation of immune system toward a Th1 response.
Methods: peripheral blood monocyte were collected from healthy donors and CD14+
cells were cultured in the presence of GM-CSF and IL-4 to differentiate in immature den-
dritic cells and stimulated at day 5 of differentiation by ox-LDL (80 micg/ml) or
lipopolysaccharide (LPS) (1 ng/ml) in the presence and absence of a blocking mono-
clonal antibody of LOX-1 (10 micg/ml). Analysis of CD-80, HLA-DR, CD-86, CD-14,
CD1a were performed by flow-cytometry at day 6. Capture of DiI labelled ox-LDL by
mature dendritic cells were studied by flow-cytometry after maturation induced by LPS or
ox-LDL in the presence or absence of LOX-1 antibody.
Results: Pre-treatment with LOX-1 antibody negatively modulates the differentiation of
MDDC induced by ox-LDL but not by LPS. Induction of maturation induced by LPS or ox-
LDL reduced the amount (mean fluorescence intensities, MFI) of DiI-labelled ox-LDL
captured by dendritic cells. Pre-treatment at day 6 of maturation with LOX-1 antibody
have no effect in cells stimulated with LPS, conversely in cells stimulated with ox-LDL,
LOX-1 antibody reduced by 75% the binding of DiI labelled ox-LDL.
Conclusions: we identified LOX-1 as one of the major receptor involved in up-take of ox-
LDL and maturation of MDDC. Moreover activation of MDDC lead to a reorganization of
membrane receptor with a dominant role of LOX-1. Inhibition of dendritic cells activation
induced by ox-LDL by the use of LOX-1 antibody could have important role in clinical sta-
bilization of patients presenting with ACS.
1122-176 NAD(P)H Dependent Superoxide Production in Human 
Platelets: The Role of Angiotensin II and Protein Kinase 
C
Sinead M. Hughes, Rick Plumb, Naglaa El- Sherbeeny, Lana J. Dixon, Adrian Devine, 
William J. Leahy, Gary E. McVeigh, Queen's University, Belfast, United Kingdom
Background: In health Endothelial Cells (ECs) have tightly controlled pathways for the
production and degradation of Superoxide (02.-). In hypertension there seems to be loss
of this control in animal/ in vtiro studies, with an increase in 02.- production mainly by the
NAD(P)H oxidase system. This increase in 02.- appears to be stimulated by a Protein
Kinase C (PKC) mediated effect on Angiotensin II (AT II) acting via the AT II type 1 recep-
tor. Platelets are known to release 02.-.In this study we postulate that the systems
responsible for 02.- production in ECs are also responsible in platelets making the latter
an excellent moel for the study of ECs.
Method:We studied 20 patients with known essential hypertension who were off medica-
tion for 4 weeks. Platelet suspensions were prepared by sequential centrifugation and
standardised assays were stimulated with AT II or Phorbol Myristate Acetate (PMA). Val-
sartan (an AT II type 1 receptor inhibitor), DPI/ Quinacrine ( a flavoprotein oxidoreductase
inhibitor) or Chelerythrine (a PKC inhibitor) were added to the platelet samples from each
individual.02.- was measured using the lucigenin-enhanced chemiluminescent technique.
Results: AT II and PMA stimulated platelet 02.- production. This was markedly reduced by
Valsartan, Chelerythrine and DPI/ Quinacrine. Conclusions: AT II stimulates an increase
in platelet production of 02.- from NAD(P)H oxidase predominantly via the AT II type 1
receptor. This is at least in part mediated by PKC activation. Platelets are thus an excel-
lent model of ECs for the study of 02.- production, in terms of both ease of accessibility
and similarity of systems.
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Delphine Yung, Greg Maislin, Allison Widlitz, Erika S. Berman Rosenzweig, Kelly 
Schmitt, Daniela Brady, Ellen O'Brien, Diane Kerstein, Evelyn M. Horn, Robyn J. Barst, 
Columbia University College of Physicians and Surgeons, New York, NY
Background: Treatment for idiopathic pulmonary arterial hypertension (IPAH) in children
has been calcium channel blockers (CCB) for acute responders (AR) with vasodilator
testing and chronic epoprostenol for nonresponders (NR). We sought to determine fac-
tors associated with long-term survival and treatment success, i.e. without death or trans-
plant, and without transition to epoprostenol for patients on CCB.
Methods: A previously identified cohort of 79 patients under age 16 diagnosed with IPAH
between 1982 and 1995 at Columbia University was followed through 2002.
Results: For AR, survival rates at 1, 5 and 10 years were 97%, 97%, and 81%, respec-
tively. For AR, success rates on CCB at 1, 5 and 10 years were 84%, 68%, and 47%. Sur-
vival rates on epoprostenol at 1, 5 and 10 years were 94%, 81%, and 61%, respectively.
Success rates on epoprostenol at 1, 5 and 10 years were 89%, 63%, and 45%. With mul-
tivariate analysis, baseline variables associated with success on CCB were AR status,
NYHA class I, II, or III, and right atrial pressure. When AR status changed to NR status,
success on CCB decreased significantly. Both survival and success on epoprostenol
were only associated with age at the start of epoprostenol.
Conclusion: These findings suggest that children with IPAH who are AR should be
treated with CCB therapy with transition to epoprostenol if they change to NR status.
Epoprostenol therapy should be considered in patients with higher NYHA class, and list-
ing for transplantation should be considered in older patients. 
1123-178 The Lonflit Study: Evaluation of Venous Thrombosis in 
5,000 Long-Haul Passengers
Belcaro Giovanni, Cesarone Maria Rosaria, Chieti University, San Valentino (Pe), Italy
The LONFLIT studies have evaluated the frequence of deep venous thrombosis (DVT)
and edema in subjects flying 7-12 hours. By ultrasound femoral, popliteal, soleal veins
were scanned. A global analysis was performed to evaluate the frequence of DVT in a
population sample including 5000 passengers; 4922 (age range 25-69; M:F=43% vs
57%) completed the study. Subjects were divided in high, moderate and low risk for DVT
(Am College of Cardiology Guidelines). Global analysis indicates the incidence of clots
detected after flights: 3.25% of subjects had a clot; most subjects (93.66%) had a vari-
able range of leg edema. An epidemiological evaluation (questionnaires) on 6448 pas-
sengers, indicates that 54% of subjects flying between 7-12 hours (age range 25-75) can
be considered at low-risk, 35% at moderate and 11% at high risk. The possible incidence
of DVT could be extrapolated to a number between 2 and 3% for the general flying popu-
lation. Our analysis excluded younger subjects (<25) and subjects older than 75 who
constitute a significant number of passengers. As 20 000 000 travellers fly every year for
more than 10 hours the problem should be considered with attention. The finding small
(<1 cm) vein clots, which may be spontaneously lysed in hours is an interesting observa-
tion of doubtful clinical value. Prevention with specific stockings, low-molecular weight
heparin (Lovenox) and antithrombotic drugs, as shown in randomized trials reduce DVT
incidence particularly in high-risk subjects.
FREQUENCE OF DVT AND EDEMA
RISK LEVEL NUMBER LOST % WITH DVT NUMBER OF DVT % WITH EDEMA
LOW 1476 58 1.35 20 88
MODERATE 1787 61 2.5 45 93
HIGH 1659 54 5.9 98 100
TOTAL 4922 173 3.25 163 93.66
